stockrow
Monday 9 November 2026
Export AVLN’s income statement to Excel — free account
Avalyn Pharma Inc.
AVLN
29.15
2.48
+9.30%
Follow AVLN
Alert me
Avalyn Pharma Inc. (AVLN) Return on invested capital
Avalyn Pharma Inc.'s return on invested capital over the twelve months to 30 June 2026 was −102.6%. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | 0.00% |
| MNKD MannKind Corporation compare | 0.00% |
| INBX Inhibrx Biosciences, Inc. compare | 0.00% |
| DRTS Alpha Tau Medical Ltd. compare | 0.00% |
| VSTM Verastem, Inc. compare | 0.00% |
| VOR Vor Biopharma Inc. compare | 0.00% |
| SGP SpyGlass Pharma, Inc. compare | 0.00% |
| AVLN Avalyn Pharma Inc. | −102.6% |
| LBRX LB Pharmaceuticals Inc compare | −1,304.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)